PROFILE |
 |
Array BioPharma thinks genomics is sexy too, but it still has a periodic table of the elements on its wall. The biopharmaceutical company focuses on creating, testing, and enhancing possible new drugs through chemistry. Array makes proprietary chemical constituents, creates and optimizes leads (for such diseases as asthma and diabetes), and performs research and development. The company charges fees for its research and development services to its partners, which include ICOS Corporation and Merck. Array also sells chemical compounds to such customers as Celltech Group and Tularik. Investors in the company include ARCH Venture Fund, Boulder Ventures, and Frazier Healthcare.
COMPETITION |
 |
Albany Molecular Research, Inc. (AMRI)
ArQule, Inc. (ARQL)
Vertex Pharmaceuticals Incorporated (VRTX)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: June
2000 Sales (mil.): 6.80
1-Yr. Sales Growth: 352.4%
Employees: 100
Revenue per employee: $68,000.00
KEY PEOPLE |
 |
Robert E. Conway
CEO
Michael Carruthers
CFO
CONTACT INFO |
 |
1885 33rd St.
Boulder, CO 80301
US
Phone: 303-381-6600
Fax: 303-449-5376
Online: Web Site
|